BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:11 PM
 | 
Sep 06, 2012
 |  BC Extra  |  Company News

German committee finalizes assessments for Zelboraf, Caprelsa

Germany's Federal Joint Committee (G-BA) issued final benefit assessments for cancer drugs Zelboraf vemurafenib and Caprelsa vandetanib that are in line with preliminary assessments from the Institute for Quality and Efficiency in Health Care (IQWiG). G-BA said Zelboraf from Roche (SIX:ROG; OTCQX:RHHBY) provides "significant" additional...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >